A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Multiple Doses of SAGE-718 Using Ketamine Challenge to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
Sponsor: Supernus Pharmaceuticals, Inc.
A PHASE1 clinical study on Healthy Volunteer, this trial is completed. The trial is conducted by Supernus Pharmaceuticals, Inc. and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE1
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Supernus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .